How to Help Your Patients Save Money on Skyrizi (Risankizumab): A Provider's Guide to Savings Programs

Skyrizi (risankizumab-rzaa) carries a list (WAC) price of approximately $22,383 per dose — exceeding $90,000 per year at list price for psoriasis or psoriatic arthritis patients receiving quarterly injections. Despite this, most commercially insured patients can access Skyrizi with minimal out-of-pocket cost when they're enrolled in the right support programs.

As the prescribing provider, you are often the most important link in connecting patients to these programs. This guide summarizes every available cost-reduction pathway for Skyrizi in 2026 and how to help patients access them.

Understanding the Cost Structure of Skyrizi

The list price is rarely what patients or payers pay. Skyrizi pricing involves several layers:

List price (WAC): ~$22,383/dose — the published list price before any discounts or rebates

Net price: What payers actually pay after negotiated rebates — typically significantly lower

Patient out-of-pocket: What your patient pays — can range from $0 (with savings card + commercial insurance) to thousands (with Medicare, poor coverage, or no insurance)

Your role as a prescriber is to help patients navigate the "patient out-of-pocket" column — and the tools to do that are well-established.

Program 1: Skyrizi Complete Savings Card

The Skyrizi Complete Savings Card is the primary cost-assistance tool for commercially insured patients. Eligible patients may pay as little as $0 per quarterly dose (for psoriasis/PsA patients) or per maintenance dose (for IBD patients).

Provider-side action: Enroll patients in Skyrizi Complete at the point of prescribing by calling 1-866-SKYRIZI (1-866-759-7494) or directing patients to SKYRIZISavingsCard.com. Don't wait until after PA approval — early enrollment streamlines the entire process.

Eligibility criteria:

Must have commercial (private) insurance — not Medicare, Medicaid, or TRICARE

Must be aged 63 years or younger

Must have a valid prescription for an FDA-approved Skyrizi indication

Important caveat: Patients whose plans have accumulator adjustment or co-pay maximizer programs may see reduced savings card benefit. Counsel patients to check with their pharmacist about their plan's specific rules.

Program 2: AbbVie Bridge Program (For PA Denials)

When a patient's PA is denied and you are filing an appeal, the AbbVie bridge program ensures treatment continuity. The program provides Skyrizi at no charge for up to 2 years — or until insurance approval is obtained, whichever comes first.

Provider-side requirements:

Patient must be commercially insured, ≤63 years old

PA denial must be on file

Confirmed appeal must be submitted (typically requires prescriber documentation)

Continued eligibility requires submitting an appeal of the coverage denial every 180 days

Program 3: myAbbVie Assist (Uninsured and Underinsured)

For patients who have no insurance or whose insurance does not cover Skyrizi, myAbbVie Assist provides the medication at no charge based on income and other eligibility criteria. There is no published income cutoff — eligibility is assessed case-by-case.

Provider-side action: Identify uninsured or underinsured patients at the point of prescribing and direct them to call 1-800-222-6885 or visit AbbVie.com/PatientAccessSupport. Your office can also initiate the referral on behalf of the patient.

Program 4: PAN Foundation IBD Fund (Medicare Patients)

Medicare patients are not eligible for the Skyrizi Complete Savings Card. However, those with Crohn's disease or ulcerative colitis may qualify for the Patient Access Network (PAN) Foundation's Inflammatory Bowel Disease fund, which provides up to $4,000 per year in out-of-pocket cost assistance.

Fund availability fluctuates throughout the year. Direct Medicare patients to panfoundation.org or 1-866-316-7263 to check current availability and apply.

Insurance Coverage Optimization Strategies

Beyond assistance programs, there are strategies to help reduce patient cost at the insurance level:

Exception to step therapy: If a patient cannot tolerate or has contraindications to step therapy alternatives, document this clearly in the PA to avoid delays.

Formulary tier placement: Skyrizi is on a preferred tier or preferred status on many commercial plans (as of November 2025 data). If your patient's plan has Skyrizi at a high cost tier, review whether a plan switch at open enrollment would lower their costs.

Medical vs. pharmacy benefit: Skyrizi IV infusions for Crohn's and UC are often covered under the medical benefit (lower cost-sharing in many plans) rather than the pharmacy benefit. Confirm which benefit covers Skyrizi for each patient.

AbbVie Field Reimbursement Manager Support

AbbVie's Field Reimbursement Managers (FRMs) can provide your practice with one-on-one support for complex cases involving unusual payer requirements, repeated PA denials, or patients who don't fit standard program eligibility. Request FRM support by calling 1-866-SKYRIZI.

Once financial assistance is secured, help your patients find a specialty pharmacy to fill their prescription using medfinder for providers. See also: Provider's Guide to Helping Patients Find Skyrizi In Stock.